SMS Pharmaceuticals Ltd (SMSPHARMA) is currently trading at 440.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

SMS Pharmaceuticals Limited manufactures Active Pharma Ingredients (APIs) and intermediates, with multiple FDA-compliant facilities in Hyderabad and Andhra Pradesh. The company is a leader in the production of APIs and leverages its extensive R&D capabilities to maintain its market position. The company reported an 80% year-on-year increase in profit after tax for Q2 FY26, driven by a strategic focus on backward integration and volume growth across key APIs. A major ₹280 crore capital expenditure program is underway, aimed at expanding production capacities and enhancing the company's market footprint by November 2026. SMS Pharmaceuticals maintains a diversified product portfolio across over 55 APIs in 14 therapeutic segments, mitigating market risks and enhancing revenue stability. Strategic partnerships, such as the joint venture with Chemo, have significantly bolstered the company's position in the regulated markets, leading to first-to-market advantage in the anti-diabetic segment.

Over the past 52 weeks, SMS Pharmaceuticals Ltd has traded between a low of ₹240.45 and a high of ₹482.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

SMS Pharmaceuticals Ltd has a market capitalization of approximately 4,148.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

SMS Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 46.36 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,148.32 Cr, SMS Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

SMS Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of SMS Pharmaceuticals Ltd is 46.36. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Standalone revenue was Rs 207.0 crore and standalone net profit was Rs 21.1 crore for Q1 FY27 (ended June 30, 2026).